Clinical trials: Fat; Liver
NAFLD, Obesity
Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.
The study in question is an interventional study with nutritional intervention. The aim of the study is to evaluate whether the adoption of two different models of Mediterranean Diet, based on the different percentage of…
- Conditions
- NAFLD, Obesity, IBS
- Trial name
- NAFLD-POS5 (NCT06275906)
- Testing
- Mediterranean diet and moderate intensity physical exercise (outdoor walking).
- Where
- Italy
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
T2DM (Type 2 Diabetes Mellitus), Fatty Liver
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
The primary objective of this study is to investigate the change in Alanine Aminotransaminase (ALT) in patients with Type 2 Diabetes Mellitus (T2DM) initiating Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, liraglutide, or…
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Fatty Liver, NAFLD
- Trial name
- ALT (NCT03233178)
- Testing
- Non-interventional
- Where
- Canada
- Volunteers
- 4,000 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Perceived Recovery
Effect of Inspiratory Muscle Training on Diaphragm and Ab-dominal Wall Muscle Thickness With Fatty Liver Density in Elderly Women: A Randomized Controlled Trial
Background: Post-menopausal estrogen decline is considered a contributing factor to sarcopenia, and inspiratory muscle training (IMT) may provide benefits in this demo-graphic.
- Trial name
- IMT AND ELDERL (NCT07168733)
- Testing
- Inspiratory muscle training, Control
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gümüşhane Universıty
NASH - Nonalcoholic Steatohepatitis, NAFLD
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT03291249
- Testing
- Foralumab, Omeprazole 20mg
- Sponsor
- Tiziana Life Sciences LTD
Non-Alcoholic Fatty Liver Disease
Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non Alcoholic Fatty Liver Disease
The main objective is to compare the accuracy of transient elastography taking into account liver steatosis determined by MRI, to liver biopsy for the diagnosis of liver fibrosis ≥F2 in patient with NAFLD.
- Trial name
- FibroMR (NCT03245606)
- Testing
- Liver biopsy, Abdominal MRI, Transient elastography
- Where
- 9 sites in France
- Volunteers
- 270 people
- Sponsor
- Rennes University Hospital
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, NAFLD
Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers
This study is to evaluate the effect of food on the pharmacokinetics of a single dose of ASC41 tablet in healthy volunteers, comparing fasting and postprandial pharmacokinetic parameters of Tmax, Cmax, AUC0-t, AUC0-∞.
- Conditions
- Healthy, NAFLD, Hyperlipidemia
- Trial name
- NCT04692025
- Testing
- ASC41 tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Elevated Liver Fat Content and Insulin Resistance
Effect of resVida on Liver Fat Content
The purpose of this study is to investigate the effects of the antioxidant "resveratrol" on liver fat content, body-composition and insulin sensitivity Resveratrol is found in grape skin, wine, peanuts, and mulberries and is…
- Trial name
- resVida NAFL (NCT01635114)
- Testing
- resveratrol
- Where
- Germany
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Nonalcoholic Steatohepatitis
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult participants with NASH.
- Trial name
- AURORA (NCT03028740)
- Testing
- Cenicriviroc
- Where
- 346 sites in United States, Australia and 26 more
- Volunteers
- 1,778 people
- Sponsor
- Tobira Therapeutics, Inc.
Obesity
Can Genetic Markers Predict Weight Loss After Gastric By-pass Surgery
There is a variability in weight loss after gastric bypass surgery for obesity despite a standardised surgical procedure. This study aims to investigate if genetic markers can predict outcome after gastric by-pass surgery in…
- Trial name
- NCT01736384
- Testing
- Gastric bypass or cholecystectomy
- Where
- 3 sites in Sweden
- Volunteers
- 2,000 people
- Sponsor
- Karolinska Institutet
Impaired Fasting Glucose, Pre Diabetes
Dietary Interventions in Prediabetes
Assessment of glucose metabolism and liver fat after 12 week dietary intervention in pre diabetes subjects. Subjects will be randomized to either high fat (olive oil supplemented),high carb/high fiber (beans supplemented) and…
- Conditions
- Impaired Fasting Glucose, Pre Diabetes, Liver Fat
- Trial name
- NCT01729078
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled…
- Trial name
- NCT01006889
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
NASH (Non-Alcoholic Steatohepatitis)
Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis
VENS is a multicenter, randomized, double-masked, placebo parallel controlled trial to evaluate the efficacy and safety of treatment with vitamin E softgel in non diabetic adults with NASH compared to treatment with placebo in…
- Trial name
- NCT02962297
- Testing
- Vitamin E softgel
- Where
- 15 sites in China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Medicine Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Obesity, Morbid
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
The study is aimed To quantify the change of adipose tissues, triglyceride in liver and pancreas and cholesterol after lifestyle intervention or bariatric surgery.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Morbid, Brown Fat, Metabolic Disease
- Trial name
- NCT03875625
- Testing
- Bariatric surgery, Dietitian led life style modification intervention, Conventional care (control)
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Non-Alcoholic Fatty Liver Disease, Machine Learning
Metabolic Subtypes of Non-Alcoholic Fatty Liver Disease
The purpose of this study was to use machine learning to explore a more precise classification of NAFLD subgroups towards informing individualized therapy.
- Trial name
- NCT05560997
- Testing
- 10-year ASCVD risk estimation
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Yan Bi
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
This study involves research about an investigational medicine called metreleptin. The reason for this study is to find out how metreleptin can improve non-alcoholic steatohepatitis or nonalcoholic fatty liver disease associated…
- Conditions
- Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
- Trial name
- NCT01679197
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
NAFLD, NASH - Nonalcoholic Steatohepatitis
Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease
The purpose of this study is to prospectively evaluate the utility of Liver Incytes in assessing NAFLD with or without advanced fibrosis in patients seen in liver clinics for suspected NAFLD diagnosis.
- Trial name
- NCT04576923
- Testing
- Velacur by Sonic Incytes
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Non-alcoholic Steatohepatitis (NASH)
Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis
The prevalence of non-alcoholic fatty liver disease (NAFLD ) in the American population is approximately 30% in adults and 10% in children, making it the most common. Cause of chronic liver disease in the United States.
- Trial name
- NCT05050721
- Testing
- CT imaging
- Where
- United States
- Sponsor
- Methodist Health System
Nonalcoholic Steatohepatitis
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes (T2DM) and characterized by insulin resistance and hepatic fat accumulation.
- Trial name
- VA NASH (NCT01002547)
- Testing
- pioglitazone, Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Non-Alcoholic Fatty Liver Disease
The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting
This study aims to measure the effect of GLP-1 analogues on non-alcoholic fatty liver disease in patients with diabetes and/or obesity in a clinical context.
- Trial name
- GLP1_NAFLD (NCT07021443)
- Testing
- non-interventional
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Universitair Ziekenhuis Brussel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.